We are very pleased to welcome Mika, a successful healthcare company, to our portfolio. With this Berlin-based startup, we now have a total of 20 portfolio companies in both funds. Mika is the first digital health application to be approved as a provisional DiGa and can therefore be prescribed and used free of charge for all cancer diseases. It helps patients to act self-determined, to motivate them and to take responsibility.
Who is Mika?
Mika accompanies patients during and after cancer therapy. Monitoring symptoms , mindfulnessand movement exercises, answers to difficult questions - Mika helps to better cope with the mental and physical consequences of the disease. Mika is the first oncology applicationapproved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a digital health application for all types of cancer . Mika is being developed in close collaboration with leading oncologists, psychooncologists and cancer researchers at Charité, Leipzig University Hospital and NCT Heidelberg.
What makes Mika interesting?
Mika addresses the most important issues related to cancer treatment, namely monitoring, information and coaching. They have a solid foundation of scientific data, on which to base their content, as well as user-friendliness of the application. Mika is a DiGA approved application and is reimbursed by the patient's health insurance. With a focus on patient care and the highest level of data security setzt Mika die Voraussetzungen für eine vertrauenswürdige Anwendung, Mika sets the stage for a trusted application that serves the best interest of patients. The Mika app was also named the 2021 Most Innovative Product in the Digital Health Application category at this year's Pharma Trend Images & Innovation Awards. At the same time, Mika won bronze at the MSD Health Awards.
We are looking forward to supporting the strong team around the two founders Gandolf Finke and Jan Simon Raue in their further development.